EUVIMEDOpdag EUVIMED
Beobachtungsstudie

Early Efficacy and Safety of Finerenone on Type 2 Diabetes‐Related Chronic Kidney Disease: A Real‐World Observational Study in China

Liyu Lin, Ziyan Shen, Zhihong Chen, Yang Li, Yiqi Su, Jie Teng, Xiaoqiang Ding, Jiaming Zhu

Diabetes/Metabolism Research and Reviews · 2025-09 · 41 (6)

DOI: 10.1002/dmrr.70078 ↗

At a glance

Beobachtungsstudie in Diabetes/Metabolism Research and Reviews, published online on 2025-08-21. Written by Liyu Lin and 7 co-authors. Institution: Department of Nephrology, Zhongshan Hospital, Shanghai Medical Center for Kidney Diseases, Fudan University, Kidney and Dialysis Institute of Shangha…. Major MEDLINE topics: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Diabetic Nephropathies, Naphthyridines. Cited 8 times so far (Crossref); 22 references. Funded by: Key Specialty Construction Project of Fujian Province, Natural Science Foundation of Xiamen, China, Natural Science Foundation of Fujian Province.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

This observational study aimed to assess the early efficacy and safety of finerenone in patients with type 2 diabetes‐related chronic kidney disease (CKD) in China with or without sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) or renin‐angiotensin system inhibitors (RASi). Materials and Methods Patients with type 2 diabetes‐related CKD who initiated finerenone therapy between March 2023 and February 2024 at Zhongshan Hospital, Fudan University were retrospectively included. All patients were followed up at least once during the 12‐week observation period. Key parameters, including urinary albumin/creatinine ratio (UACR), 24‐h urine protein, serum creatinine, and potassium (K + ) levels, were recorded. Estimated glomerular filtration rate (eGFR) was calculated based on serum creatinine using the Collaborative Epidemiological Formula for Chronic Kidney Disease.

Results

A total of 105 patients (mean age, 59.4 ± 13.3 years; 81 males and 24 females) were included, with 82.9% diagnosed with diabetic nephropathy. After 12 weeks of finerenone treatment, UACR declined by 39.55%, with consistent results across all treatment groups, regardless of baseline eGFR or concomitant SGLT‐2i/RASi use. A decline in eGFR > 30% occurred in 6.67% of patients, while a > 10% decline occurred in 61.9%. Hyperkalemia (serum K + > 5.5 mmol/L) was observed in 8.57% of patients, mainly in those with eGFR < 60 mL/min/1.73 m 2 , with the highest incidence (37.5%) in those with eGFR < 30 mL/min/1.73 m 2 .

Conclusions

Finerenone effectively reduced albuminuria in patients with type 2 diabetes‐related CKD; however, close monitoring of eGFR and serum K + levels is essential, particularly in those with reduced baseline renal function.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicDiabetic NephropathiesNaphthyridinesHumansMaleFemaleMiddle AgedRetrospective StudiesGlomerular Filtration RateAgedChinaFollow-Up StudiesSodium-Glucose Transporter 2 InhibitorsPrognosisAlbuminuriaBiomarkers

Author keywords

early efficacyfinerenonesafetytype 2 diabetes‐related CKD

Substances

finerenoneNaphthyridinesSodium-Glucose Transporter 2 InhibitorsBiomarkers

Authors and institutions

  • Department of Nephrology, Zhongshan Hospital, Shanghai Medical Center for Kidney Diseases, Fudan University, Kidney and Dialysis Institute of Shanghai, Shanghai, China.
  • Department of Nephrology, Zhongshan Hospital (Xiamen), Xiamen Clinical Quality Control Center of Nephrology, Fudan University, Xiamen, China.

Funding

  • Key Specialty Construction Project of Fujian Province
  • Natural Science Foundation of Xiamen, China
  • Natural Science Foundation of Fujian Province
  • Zhongshan Hospital

Cite

APA

Lin, L., Shen, Z., Chen, Z., Li, Y., Su, Y., Teng, J., Ding, X., & Zhu, J. (2025). Early Efficacy and Safety of Finerenone on Type 2 Diabetes‐Related Chronic Kidney Disease: A Real‐World Observational Study in China. Diabetes/Metabolism Research and Reviews, 41(6). https://doi.org/10.1002/dmrr.70078

Vancouver

Lin L, Shen Z, Chen Z, Li Y, Su Y, Teng J, et al. Early Efficacy and Safety of Finerenone on Type 2 Diabetes‐Related Chronic Kidney Disease: A Real‐World Observational Study in China. Diabetes/Metabolism Research and Reviews. 2025;41(6). doi:10.1002/dmrr.70078

BibTeX
@article{Lin2025,
  author = {Lin, Liyu and Shen, Ziyan and Chen, Zhihong and Li, Yang and Su, Yiqi and Teng, Jie and Ding, Xiaoqiang and Zhu, Jiaming},
  title = {Early Efficacy and Safety of Finerenone on Type 2 Diabetes‐Related Chronic Kidney Disease: A Real‐World Observational Study in China},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2025},
  volume = {41},
  number = {6},
  doi = {10.1002/dmrr.70078}
}
Start for free →